With 13 out of 15 companies, the largest crossover rounds in Life Sciences since 2016 are clearly dominated by biotech companies. However, the largest crossover financing was raised by the Chinese healthcare services company Ping An Good Doctor in the amount of EUR 939m. Until its IPO in 2018, the company had raised in total astonishing EUR 1,380m.
In Europe, CureVac received the largest crossover financing in the amount of EUR 560m and even exceeds the total capital raised until IPO of Ping An Good Doctor by EUR 75m!
In the US, Lyell Immunopharma leads the ranking with its EUR 451m crossover round in 2020. Due to the extraordinary high number of large financing rounds in the US, the top 5 crossover transactions start at significantly higher volumes than in Europe or China.
About FCF Life Sciences
FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.
Learn more about FCF Life Sciences, click here.
We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.
To hear from us on the latest insights, please sign up here: